PA
MRNA icon

Profund Advisors’s Moderna MRNA Stock Holding History

Profund Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.32M Sell
33,142
-5,870
-15% -$304K 0.06% 166
2026
Q1 		$1.98M Sell
39,012
-38,884
-50% -$1.81M 0.07% 209
2025
Q4 		$2.3M Buy
77,896
+5,159
+7% +$140K 0.07% 188
2025
Q3 		$1.88M Sell
72,737
-664
-0.9% -$18.5K 0.06% 204
2025
Q2 		$2.03M Buy
73,401
+7,659
+12% +$202K 0.07% 183
2025
Q1 		$1.86M Buy
65,742
+3,494
+6% +$124K 0.08% 187
2024
Q4 		$2.59M Sell
62,248
-15,979
-20% -$764K 0.09% 150
2024
Q3 		$5.23M Buy
78,227
+22,009
+39% +$2.02M 0.2% 84
2024
Q2 		$6.68M Buy
56,218
+9,719
+21% +$1.23M 0.25% 62
2024
Q1 		$4.95M Sell
46,499
-6,434
-12% -$649K 0.19% 80
2023
Q4 		$5.26M Buy
52,933
+10,149
+24% +$854K 0.23% 73
2023
Q3 		$4.42M Buy
42,784
+8,697
+26% +$970K 0.24% 70
2023
Q2 		$4.14M Buy
34,087
+3,979
+13% +$531K 0.22% 66
2023
Q1 		$4.62M Sell
30,108
-25,353
-46% -$4.18M 0.29% 55
2022
Q4 		$9.96M Sell
55,461
-1,302
-2% -$213K 0.65% 26
2022
Q3 		$6.71M Sell
56,763
-4,420
-7% -$671K 0.48% 35
2022
Q2 		$8.74M Sell
61,183
-9,974
-14% -$1.43M 0.56% 30
2022
Q1 		$12.3M Sell
71,157
-15,014
-17% -$2.53M 0.51% 31
2021
Q4 		$21.9M Sell
86,171
-9,175
-10% -$2.68M 0.72% 24
2021
Q3 		$36.7M Buy
95,346
+10,816
+13% +$3.99M 1.24% 11
2021
Q2 		$19.9M Sell
84,530
-2,291
-3% -$409K 0.67% 23
2021
Q1 		$11.4M Buy
86,821
+1,404
+2% +$203K 0.44% 38
2020
Q4 		$8.92M Buy
85,417
+6,851
+9% +$693K 0.39% 42
2020
Q3 		$5.56M Buy
78,566
+13,078
+20% +$912K 0.29% 60
2020
Q2 		$4.21M Buy
65,488
+26,674
+69% +$1.46M 0.23% 83
2020
Q1 		$1.16M Sell
38,814
-14,168
-27% -$326K 0.09% 213
2019
Q4 		$1.04M Buy
52,982
+5,869
+12% +$104K 0.05% 342
2019
Q3 		$750K Buy
+47,113
New +$696K 0.04% 428

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Profund Advisors's MRNA Position: Q2 2026 in Review

Profund Advisors reduced its Moderna (MRNA) stake by 15% in Q2 2026, selling an estimated $304K and leaving 33,142 shares worth $2.32M. The position accounts for 0.06% of the portfolio, ranked #166.

Profund Advisors first reported a position in MRNA in Q3 2019 and has held it in 28 quarters since. The position peaked at $36.7M in Q3 2021. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Profund Advisors held 33,142 shares of Moderna worth $2.32M as of Q2 2026.
  • Profund Advisors sold 5,870 Moderna shares in Q2 2026, an estimated $304K.
  • Moderna made up 0.06% of Profund Advisors's portfolio in Q2 2026, its #166 holding.
  • Profund Advisors first reported a position in Moderna in Q3 2019 and has held it in 28 quarters since.
  • Profund Advisors's Moderna position peaked at $36.7M in Q3 2021.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.